<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00241124</url>
  </required_header>
  <id_info>
    <org_study_id>CVAL489A2420</org_study_id>
    <nct_id>NCT00241124</nct_id>
  </id_info>
  <brief_title>Comparison Of Morning And Evening Dosing Of Valsartan And Lisinopril In Patients With Diabetes</brief_title>
  <official_title>A Randomized, Double Blind, Double Dummy, Parallel Group, Active-Controlled Study To Evaluate The Effectiveness Of Morning Versus Evening Doses Of 320 Mg Valsartan Versus 40 Mg Lisinopril On The 24 Hour Blood Pressure Profile In Patients With Hypertension And Non-Insulin Dependent Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      A study comparing the antihypertensives Valsartan and Lisinporil when doses are in the
      morning and comparing a morning dose of Valsartan with an evening dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average 24 hour blood pressure less than 130/80 mmHg after 26 weeks</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in systolic 24 hour blood pressure after 12 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline manual blood pressure and pulse pressure after 26 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline markers of endothelial function, fibrosis, and other blood measurements of hypertension after 12 and 26 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ambulatory blood pressure measurements at various timepoints up to 26 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline heart size after 26 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events, serious adverse events, laboratory values, physical examinations, vital signs for up to 26 weeks</measure>
  </secondary_outcome>
  <enrollment type="Actual">1099</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valsartan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lisinopril</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Hypertension defined by a MSSBP &gt;=150 mmHg (untreated patients) or patients on current
        anti-hypertensive treatment who remain uncontrolled (i.e. MSSBP &gt;140 mmHg)

          -  Randomisation mean 24h blood pressure above 130/80 mmHg

          -  In addition the patients must fulfill, at least, one of the following criteria:

        Controlled type II Diabetes mellitus Hypercholesteremia, currently treated with
        lipid-lowering drugs Metabolic syndrome MI, CABG or PTCA more than one year ago Stroke or
        transient ischemic cerebral attack more than one year ago Documented history of peripheral
        vascular disease, increased IMT, or carotid plaques Documented history of LVH Elderly &gt;65
        years

        Exclusion Criteria:

          -  - MSSBP &gt;=180 mmHg and/or MSDBP &gt;= 110 mmHg at any time from Visit 1 to Visit 3

          -  Inability to discontinue all prior anti-hypertensive medications safely for a period
             of three weeks

          -  Mandatory indication for any concomitant medication for coronary artery disease or any
             other disease that is not allowed during this study.

        Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Investigative Centers</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2005</study_first_submitted>
  <study_first_submitted_qc>October 17, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2005</study_first_posted>
  <last_update_submitted>November 22, 2011</last_update_submitted>
  <last_update_submitted_qc>November 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>valsartan</keyword>
  <keyword>morning/evening dosing</keyword>
  <keyword>lisinopril</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Lisinopril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

